Sofosbuvir and Daclatasvir Combination Therapy in a Liver Transplant Recipient With Severe Recurrent Cholestatic Hepatitis C
dc.contributor.author | Fontana, R. J. | en_US |
dc.contributor.author | Hughes, E. A. | en_US |
dc.contributor.author | Bifano, M. | en_US |
dc.contributor.author | Appelman, H. | en_US |
dc.contributor.author | Dimitrova, D. | en_US |
dc.contributor.author | Hindes, R. | en_US |
dc.contributor.author | Symonds, W. T. | en_US |
dc.date.accessioned | 2013-06-18T18:32:57Z | |
dc.date.available | 2014-08-01T19:11:33Z | en_US |
dc.date.issued | 2013-06 | en_US |
dc.identifier.citation | Fontana, R. J.; Hughes, E. A.; Bifano, M.; Appelman, H.; Dimitrova, D.; Hindes, R.; Symonds, W. T. (2013). "Sofosbuvir and Daclatasvir Combination Therapy in a Liver Transplant Recipient With Severe Recurrent Cholestatic Hepatitis C ." American Journal of Transplantation 13(6): 1601-1605. <http://hdl.handle.net/2027.42/98302> | en_US |
dc.identifier.issn | 1600-6135 | en_US |
dc.identifier.issn | 1600-6143 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/98302 | |
dc.description.abstract | Recurrent HCV infection following liver transplantation can lead to accelerated allograft injury that is difficult to treat with interferon. The aim of this study is to describe the first ever use of an interferon‐free, all oral regimen in a liver transplant recipient with severe recurrent HCV. A 54‐year‐old male with HCV genotype 1b developed severe cholestatic HCV at 6 months posttransplant with ascites, AST 503 IU/mL, alkaline phosphatase of 298 IU/mL, HCV RNA of 12 000 000 IU/mL, and histological cholestasis with pericellular fibrosis. Sofosbuvir, an HCV polymerase inhibitor (400 mg/day), and daclatasvir, an HCV NS5A replication complex inhibitor (60 mg/day), were co‐administered for 24 weeks. Within 4 weeks of initiating treatment, serum HCV RNA levels became undetectable and liver biochemistries normalized with concomitant resolution of ascites. The patient achieved a sustained virological response with undetectable HCV RNA at 9 months posttreatment. During and following treatment, the daily dose and blood level of tacrolimus remained stable and unchanged. The rapid and sustained suppression of HCV replication in this liver transplant recipient provides great promise for the use of combination oral antiviral regimens in other immunosuppressed and interferon refractory HCV patients. A patient with severe cholestatic hepatitis C virus genotype 1b infection at nine months after liver transplantation was successfully treated with a six‐month course of oral sofosbuvir in combination with daclatasvir and remains HCV RNA negative during posttreatment follow‐up with improved liver biochemistries and health. | en_US |
dc.publisher | Wiley Periodicals, Inc. | en_US |
dc.subject.other | Hepatitis C | en_US |
dc.subject.other | Direct‐Acting Antiviral Agents | en_US |
dc.subject.other | Calcineurin Inhibitors | en_US |
dc.subject.other | Polymerase Inhibitors | en_US |
dc.title | Sofosbuvir and Daclatasvir Combination Therapy in a Liver Transplant Recipient With Severe Recurrent Cholestatic Hepatitis C | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Medicine (General) | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.identifier.pmid | 23593993 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/98302/1/ajt12209.pdf | |
dc.identifier.doi | 10.1111/ajt.12209 | en_US |
dc.identifier.source | American Journal of Transplantation | en_US |
dc.identifier.citedreference | Picciotto FP, Tritto G, Lanza AG, et al. Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation. J Hepatol 2007; 46: 459 – 465. | en_US |
dc.identifier.citedreference | Veldt BJ, Poterucha JJ, Watt KDS, et al. Impact of pegylated interferon and ribavirin treatment on graft survival in liver transplant patients with recurrent HCV infection. Am J Transpl 2008; 8: 1 – 8. | en_US |
dc.identifier.citedreference | Sulkowski MJ, Gardiner D, Rodriguez‐Torres M, et al. High rate of sustained virological response with all‐oral combination of daclatasvir (NS5A inhibitor) plus sofosbuvir (nucleotide NS5B inhibitor), +/− ribavirin, in treatment naïve patients with chronically infected with HCV genotype 1, 2 and 3 (Abstract). Hepatology 2012; 56: LB#2. | en_US |
dc.identifier.citedreference | Jacobson IM, Dimitrova DI, Hughes EA, et al. Safety profile of Daclatasvir in combination with peginterferon alfa and ribavirin in 1100 patients with chronic HCV infection treated in Phase 2 studies. J Hepatol 2013; (Accepted EASL Abstract). | en_US |
dc.identifier.citedreference | Jacobson IM, Lawitz E, Lalezari J, et al. GS 0‐7977 400 mg q d safety and tolerability in the over 500 patients treated for at least 12 weeks (Abstract). J Hepatol 2012; 56: S441. | en_US |
dc.identifier.citedreference | Cornpropst MT, Denning JM, Clemons D, et al. The effect of renal impairment and end stage renal disease on the single‐dose pharmacokinetics of PSI‐7977. J Hepatol 2012; 56: S431. | en_US |
dc.identifier.citedreference | Hughes EA, Appelman H, Hindes R, Dimitrova D, Bifano M. Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver Retransplantation. Liver Transpl 2012; 18: 1053 – 1059. | en_US |
dc.identifier.citedreference | Verna ED, Brown RS. Hepatitis C virus and liver transplantation. Clin Liv Dis 2006; 10: 919 – 929. | en_US |
dc.identifier.citedreference | Forman LM, Lewis JD, Berlin JA, Feldman HL, Lucey MR. The association between hepatitis C infection and survival after liver transplantation. Gastroenterology 2002; 122: 889 – 896. | en_US |
dc.identifier.citedreference | Gane EJ, Naoumov NV, Qian KP, et al. A longitudinal analysis of hepatitis C virus replication following liver transplantation. Gastroenterology 1996; 110: 167 – 177. | en_US |
dc.identifier.citedreference | Guillouche P, Feray C. Systematic review: Anti‐viral therapy of recurrent hepatitis C after liver transplantation. Aliment Pharmacol Ther 2011; 33: 163 – 174. | en_US |
dc.identifier.citedreference | Levitsky J, Fiel MI, Norvell JP, et al. Risk for immune‐mediated graft dysfunction in liver transplant recipients with recurrent HCV infection treated with pegylated Interferon. Gastroenterology 2012; 142: 1132 – 1139. | en_US |
dc.identifier.citedreference | Hulskotte E, Gupta S, Xuan F, et al. Pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers. Hepatology 2012; 56: 1622 – 1630. | en_US |
dc.identifier.citedreference | Garg V, van Heeswijk R, Lee JE, Alves K, Nadkarni P, Luo X. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology 2011; 54: 20 – 27. | en_US |
dc.identifier.citedreference | Coilly A, Roche B, Dumortier J, et al. Efficacy and safety of protease inhibitors for hepatitis C recurrence after liver transplantation: A first multicentric experience (Abstract). Hepatology 2012; 56 (Suppl 1): A#9. | en_US |
dc.identifier.citedreference | Pungapong S, Murphy JL, Henry TM, et al. Preliminary experience using telaprevir with peginterferon and ribavirin for treatment of HCV genotype 1 after liver transplantation (Abstract). Hepatology 2012; 56 (Suppl 1): A#10. | en_US |
dc.identifier.citedreference | Lok ASF, Gardiner DF, Lawitz E, et al. Preliminary study of two oral antiviral agents for hepatitis C genotype 1. NEJM 2012; 366: 216 – 224. | en_US |
dc.identifier.citedreference | Pol S, Ghalib RH, Rustgi V, et al. Daclatasvir for previously untreated chronic hepatitis C genotype‐1 infection: A randomized, parallel‐group, double‐blind, placebo controlled, dose finding, phase 2a. Trial Lancet Inf Dis 2012; 12: 671 – 677. | en_US |
dc.identifier.citedreference | Gane EJ, Stedman CA, Hyland RH, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. NEJM 2013; 368: 34 – 44. | en_US |
dc.identifier.citedreference | Hassanein T, Lawitz E, Crespo I, et al. Once daily sofosbuvir (GS 7977) plus PEG/RBV: High early response rates are maintained during post‐treatment follow‐up in treatment naïve patient with HCV Genotype 1, 4 and 6 infection in the ATOMIC study (Abstract). Hepatology 2012; 56 (Suppl 1): #230. | en_US |
dc.identifier.citedreference | Bifano M, Sevinsky H, Persson A, et al. Daclatasvir (DCV; BMS‐790052) has no clinically significant effect on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and norgestimate in healthy female subjects (Abstract). Hepatology 2011; 54 (Suppl 1): A #1340. | en_US |
dc.identifier.citedreference | Mathias A, Cornpropst M, Clemons D, Denning J, Symonds WT. NO clinically significant pharmacokinetic drug‐drug interactions between Sofosbuvir (GS‐7977) and the immunosuppressants cyclosporine A or Tacrolimus in health volunteers (Abstract). Hepatology 2012; 56 (Suppl 1): A1869. | en_US |
dc.identifier.citedreference | Narang TK, Ahrens W, Russo MW. Post liver transplant cholestatic hepatitis C: AA systematic review of clinical and pathological findings and application of consensus criteria. Liver Transpl 2010; 16: 1228 – 1235. | en_US |
dc.identifier.citedreference | Selzner N, Guindi M, Renner EL, Berenguer M. Immune‐mediated complications of the graft in interferon‐treated hepatitis C positive liver transplant recipients. J Hepatol 2011; 55: 207 – 217. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.